These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
109 related articles for article (PubMed ID: 12201497)
1. Phase II trial of pyrazoloacridine in advanced non-small cell carcinoma of the lung--a Kansas Cancer Institute and Thompson Cancer Survival Center Study. Bastasch M; Panella TJ; Kretzschmer SL; Graham D; Mayo M; Williamson S Invest New Drugs; 2002 Aug; 20(3):339-42. PubMed ID: 12201497 [TBL] [Abstract][Full Text] [Related]
2. A phase II trial of pyrazoloacridine (PZA) in squamous carcinoma of the cervix--a Gynecologic Oncology Group Study. Plaxe SC; Blessing JA; Lucci JA; Hurteau JA Invest New Drugs; 2001; 19(1):77-80. PubMed ID: 11291835 [TBL] [Abstract][Full Text] [Related]
3. Phase II study of pyrazoloacridine in patients with advanced colorectal carcinoma. Zalupski MM; Philip PA; LoRusso P; Shields AF Cancer Chemother Pharmacol; 1997; 40(3):225-7. PubMed ID: 9219505 [TBL] [Abstract][Full Text] [Related]
4. Phase I/II trial of pyrazoloacridine and carboplatin in patients with recurrent glioma: a North Central Cancer Treatment Group trial. Galanis E; Buckner JC; Maurer MJ; Reid JM; Kuffel MJ; Ames MM; Scheithauer BW; Hammack JE; Pipoly G; Kuross SA Invest New Drugs; 2005 Oct; 23(5):495-503. PubMed ID: 16133802 [TBL] [Abstract][Full Text] [Related]
5. Evaluation of pyrazoloacridine in patients with advanced pancreatic carcinoma. Zalupski MM; Shields AF; Philip PA; Kraut M; LoRusso P; Heilbrun LK; Vaitkevicius V Invest New Drugs; 1998; 16(1):93-6. PubMed ID: 9740550 [TBL] [Abstract][Full Text] [Related]
6. A phase II pharmacodynamic study of pyrazoloacridine in patients with metastatic colorectal cancer. Pelley R; Ganapathi R; Wood L; Rybicki L; McLain D; Budd GT; Peereboom D; Olencki T; Bukowski RM Cancer Chemother Pharmacol; 2000; 46(3):251-4. PubMed ID: 11021744 [TBL] [Abstract][Full Text] [Related]
7. Phase I and pharmacologic studies of pyrazoloacridine, a novel DNA intercalating agent, on single-dosing and multiple-dosing schedules. Rowinsky EK; Noe DA; Grochow LB; Sartorious SE; Bowling MK; Chen TL; Lubejko BG; Kaufmann SH; Donehower RC J Clin Oncol; 1995 Aug; 13(8):1975-84. PubMed ID: 7636538 [TBL] [Abstract][Full Text] [Related]
8. Phase II trial of pyrazoloacridine as second-line therapy for patients with unresectable or metastatic transitional cell carcinoma. Dodd PM; McCaffrey JA; Mazumdar M; Icasiano E; Higgins G; Herr H; Bajorin DF Invest New Drugs; 2000 Aug; 18(3):247-51. PubMed ID: 10958593 [TBL] [Abstract][Full Text] [Related]
9. Phase II study of pyrazoloacridine in metastatic renal cell carcinoma. Kuebler JP; King GW; Triozzi P; Moore T; Kraut EH Invest New Drugs; 2001; 19(4):327-8. PubMed ID: 11561693 [No Abstract] [Full Text] [Related]
10. A phase I pharmacologic and pharmacodynamic study of pyrazoloacridine given as a weekly 24-hour continuous intravenous infusion in adult cancer patients. Grem JL; Harold N; Keith B; Chen AP; Kao V; Takimoto CH; Hamilton JM; Pang J; Pace M; Jasser GB; Quinn MG; Monahan BP Clin Cancer Res; 2002 Jul; 8(7):2149-56. PubMed ID: 12114415 [TBL] [Abstract][Full Text] [Related]
11. Phase II trial of pyrazoloacridine in recurrent platinum-resistant ovarian cancer: a Gynecologic Oncology Group study. Plaxe SC; Blessing JA; Morgan MA; Carlson J; Am J Clin Oncol; 2002 Feb; 25(1):45-7. PubMed ID: 11823695 [TBL] [Abstract][Full Text] [Related]
12. Phase II trial of pyrazoloacridine in recurrent platinum-sensitive ovarian cancer: a Gynecologic Oncology Group study. Plaxe SC; Blessing JA; Bookman MA; Creasman WT Gynecol Oncol; 2002 Jan; 84(1):32-5. PubMed ID: 11748972 [TBL] [Abstract][Full Text] [Related]
13. Phase II trial of pyrazoloacridine (NSC#366140) in patients with metastatic breast cancer. Ramaswamy B; Mrozek E; Kuebler JP; Bekaii-Saab T; Kraut EH Invest New Drugs; 2011 Apr; 29(2):347-51. PubMed ID: 19844661 [TBL] [Abstract][Full Text] [Related]
14. Phase I trial and pharmacokinetic study of pyrazoloacridine in children and young adults with refractory cancers. Berg SL; Blaney SM; Adamson PC; O'Brien M; Poplack DG; Arndt C; Blatt J; Balis FM J Clin Oncol; 1998 Jan; 16(1):181-6. PubMed ID: 9440741 [TBL] [Abstract][Full Text] [Related]
15. Phase II trial of pyrazoloacridine in patients with persistent or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study. Plaxe SC; Blessing JA; Husseinzadeh N; Webster KD; Rader JS; Dunton CJ Gynecol Oncol; 2002 Feb; 84(2):241-4. PubMed ID: 11812081 [TBL] [Abstract][Full Text] [Related]
16. A phase I and pharmacologic study of pyrazoloacridine and cisplatin in patients with advanced cancer. Dees EC; Rowinsky EK; Noe DA; O'Reilly S; Adjei AA; Elza-Brown K; Donehower RC Invest New Drugs; 2003 Feb; 21(1):75-84. PubMed ID: 12795532 [TBL] [Abstract][Full Text] [Related]
17. A phase II trial of pyrazoloacridine (PZA) in squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Plaxe SC; Blessing JA; Olt G; Husseinzadah N; Lentz SS; DeGeest K; Valea FA Cancer Chemother Pharmacol; 2002 Aug; 50(2):151-4. PubMed ID: 12172981 [TBL] [Abstract][Full Text] [Related]
18. Phase II study of taxol, merbarone, and piroxantrone in stage IV non-small-cell lung cancer: The Eastern Cooperative Oncology Group Results. Chang AY; Kim K; Glick J; Anderson T; Karp D; Johnson D J Natl Cancer Inst; 1993 Mar; 85(5):388-94. PubMed ID: 8094467 [TBL] [Abstract][Full Text] [Related]
19. Phase II trial of pyrazoloacridine in patients with cisplatin-refractory germ cell tumors. Vuky J; McCaffrey J; Ginsberg M; Mariani T; Bajorin DF; Bosl GJ; Motzer RJ Invest New Drugs; 2000 Aug; 18(3):265-7. PubMed ID: 10958596 [TBL] [Abstract][Full Text] [Related]
20. A phase II study of pyrazoloacridine in patients with advanced renal cell carcinoma. Berg WJ; McCaffrey J; Schwartz LH; Mariani T; Mazumdar M; Motzer RJ Invest New Drugs; 1998-1999; 16(4):337-40. PubMed ID: 10426668 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]